Urogen Pharma (URGN) Stock Statistics & Valuation Metrics

Urogen Pharma has a market cap or net worth of $899.84M. The enterprise value is $623.47M.

Urogen Pharma has 46,264,133 shares outstanding. The number of shares has decreased by -2.65% in one year.

Urogen Pharma’s return on equity (ROE) is 14.41 and return on invested capital (ROIC) is -40.77%.

The current PE Ratio of Urogen Pharma is ―. Urogen Pharma’s PEG ratio is ―.

In the last 12 months, Urogen Pharma had revenue of 90.40M and earned -126.87M in profits. Earnings per share was -2.96.

In the last 12 months, operating cash flow was -123.13M and capital expenditures -396.00K, giving a free cash flow of -123.53M billion.

Urogen Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Urogen Pharma upcoming earnings date is Nov 17, 2025, Before Open (Confirmed).

Urogen Pharma as a current ratio of 6.01, with Debt / Equity ratio of -134.85%

In the past 12 months, Urogen Pharma has paid 2.83M in taxes.

Urogen Pharma EV to EBITDA ratio is -3.70, with an EV/FCF ratio of -4.20.

Urogen Pharma has $156.95M in cash and marketable securities with $125.92M in debt, giving a net cash position of -$31.03M billion.

Gross margin is 88.54%, with operating margin of -107.06%, and net profit margin of -140.35%.

The average price target for Urogen Pharma is $32.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy